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ABSTRACT The opportunistic pathogen Candida is one of the most common causes of nosocomial bloodstream infections. Be-
cause candidemia is associated with highmortality rates and because the incidences of multidrug-resistant Candida are increas-
ing, efforts to identify novel targets for the development of potent antifungals are warranted. Here, we describe the structure and
function of the first member of a family of protein phosphatases that is specific to fungi, protein phosphatase Z1 (PPZ1) from
Candida albicans. We show that PPZ1 not only is active but also is as susceptible to inhibition by the cyclic peptide inhibitor
microcystin-LR as its most similar human homolog, protein phosphatase 1 (PP1 [GLC7 in the yeast Saccharomyces cerevi-
siae]). Unexpectedly, we also discovered that, despite its 66% sequence identity to PP1, the catalytic domain of PPZ1 contains
novel structural elements that are not present in PP1. We then used activity and pulldown assays to show that these structural
differences block a large subset of PP1/GLC7 regulatory proteins from effectively binding PPZ1, demonstrating that PPZ1 does
not compete with GLC7 for its regulatory proteins. Equally important, these unique structural elements provide new pockets
suitable for the development of PPZ1-specific inhibitors. Together, these studies not only reveal why PPZ1 does not negatively
impact GLC7 activity in vivo but also demonstrate that the family of fungus-specific phosphatases—especially PPZ1 from C. al-
bicans—are highly suitable targets for the development of novel drugs that specifically target C. albicanswithout cross-reacting
with human phosphatases.
IMPORTANCE Candida albicans is a medically important human pathogen that is the most common cause of fungal infections
in humans. In particular, approximately 46,000 cases of health care-associated candidiasis occur each year in the United States.
Because these infections are associated with highmortality rates and because multiple species of Candida are becoming increas-
ingly resistant to antifungals, there are increasing efforts to identify novel targets that are essential for C. albicans virulence.
Here we use structural and biochemical approaches to elucidate how amember of a fungus-specific family of enzymes, serine/
threonine phosphatase PPZ1, functions in C. albicans. We discovered multiple unique features of PPZ1 that explain why it does
not cross-react with, and in turn compete for, PP1-specific regulators, a long-standing question in the field. Most importantly,
however, these unique features identified PPZ1 as a potential target for the development of novel antifungal therapeutics that
will provide new, safe, and potent treatments for candidiasis in humans.
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Candida albicans is an opportunistic fungal pathogen thatcauses candidemia and is the most common cause of health
care-associated Candida bloodstream infections in the United
States (1). In the past, the majority of candidemia patients were
immunocompromised (i.e., individuals with HIV or transplant
recipients on immunosuppressant drugs, among others). However,
the numbers of nonimmunocompromised patients contracting can-
didemia have been steadily increasing, with an estimate of 7,000 to
28,000 patients contracting nosocomial candidemia annually (2).
Because the mortality rate of candidemia is 40%, these infections
result in ~2,800 to 11,200 deaths per year. Unfortunately, these
numbers are expected to increase as multiple species of Candida
are becoming increasingly resistant to antifungal medications, in-
cluding fluconazole and echinocandins (3). Although a combina-
tion of the well-established calcineurin (CN) drugs FK-506 and
cyclosporine (CSA) given with the fungal inhibitor fluconazole
has resulted in the very potent killing ofC. albicans (4), the immu-
nosuppressant functions of FK-506 and CSA make their use in
humans problematic. Furthermore,C. albicans-specificCN inhib-
itors are unlikely to be achievable due to the 100% conservation of
the CN active and substrate binding sites (5). Given the pressing
need for new, potent antifungals, efforts to identify novel protein
targets that are essential for virulence and unique toC. albicans are
warranted.
Eukaryotes contain multiple genes that encode serine/threo-
nine protein phosphatase 1 (PP1 [in humans, PP1, PP1, and
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PP1]). PP1 regulates diverse and essential biological processes by
dephosphorylating a variety of protein substrates. Although the
intrinsic substrate specificity of PP1 is very low, by interacting
with regulatory proteins to form distinct holoenzymes (~200 bio-
chemically confirmed PP1 interactors), PP1 achieves high speci-
ficity (6–8). More than two decades ago, it was discovered that
budding yeast (Saccharomyces cerevisiae), fission yeast (Schizosac-
charomyces pombe), and the opportunistic fungus Candida albi-
cans also carry a PP1 gene, coding for GLC7, Dis2, and GLC7-like,
respectively (Fig. 1). There is ~80% sequence identity between
C. albicans GLC7 and human PP1 isoforms (“GLC7” will be used
here to refer to the PP1 homolog in fungal species) (9). Like PP1,
GLC7 controls a plethora of essential biological processes, and its
activity is regulated by its interaction with multiple regulatory
proteins,many of which are conserved in humans (8). However, it
was also discovered that fungi express a unique family of PP1-like
genes, which include those coding for PPZ1 and PPQ1/Sal6 (10,
11). UnlikeGLC7, these families of fungus-specific PP1-like phos-
phatases consist of two distinct domains: an N-terminal domain
that is enriched in serines and is predicted to be unstructured (i.e.,
a member of the intrinsically disordered protein [IDP] family)
and a C-terminal catalytic domain that has high sequence similar-
ity to GLC7 (Fig. 1). This suggests that the fungus-specific phos-
phatases may also bind the GLC7-specific regulatory proteins.
This was confirmed in S. cerevisiae, in which yeast two-hybrid
studies demonstrated that S. cerevisiae PPZ1 (ScPPZ1) binds
some, but not all, S. cerevisiaeGLC7 (ScGLC7)-specific regulatory
proteins (12). However, the molecular determinants that explain
why fungus-specific phosphatases bind only a subset of the GLC7-
specific regulators are still largely unknown.
Furthermore, not only is PPZ1 important for cation homeo-
stasis and cell wall biosynthesis, it is also critical for C. albicans
virulence (13, 14). Namely, deletion of the Ppz1 gene reduces the
ability of C. albicans to infect mice, a function that can be rescued
by the reintegration of a single copy of the Ppz1 gene. In addition,
PPZ1 has also been shown to play a role in the morphological
changes in C. albicans associated with infectivity: that is, the tran-
sition from the yeast to the hyphal form. This is because the dele-
tion of Ppz1 reduces the rate of hyphal growth (15). Together,
these data suggest that the specific inhibition of PPZ1 will prevent
this morphological transition and, as a consequence, block C. al-
bicans infectivity without killing the commensal pathogen. The
fungistatic effect of such a treatment would be more beneficial
than eliminatingC. albicans altogether as the latter might result in
uncontrolled bacterial proliferation. Here, we used X-ray crystal-
lography and biochemistry to elucidate the structural and func-
tional characteristics of PPZ1 that are unique to the fungus-
specific family of phosphatases. We discovered novel structural
elements in PPZ1 that not only explain why PPZ1 binds less effec-
tively to GLC7 regulators but also define new interaction surfaces
that may be leveraged for the development of novel, effective an-
tifungal therapeutics.
RESULTS
PPZ1cat is an active phosphatase with an atypical C terminus.
Like other fungus-specific phosphatases, C. albicans PPZ1
(484 amino acids [aa], 54.4 kDa) has two domains: an N-terminal
intrinsically disordered protein (IDP) domain (aa 1 to 170
[PPZ1Nterm]) and a C-terminal catalytic domain (aa 171 to 484
[PPZ1cat]) (14, 16). PPZ1cat and human PP1 exhibit 66% se-
quence identity throughout their catalytic domains, and the 6 res-
idues that coordinate the active site metals are 100% conserved
(Fig. 1; see Fig. S1 in the supplemental material). Accordingly,
full-length PPZ1 (PPZ1FL) and its individual domains (PPZ1Nterm
and PPZ1cat) are readily isolated from Escherichia coli. In addition,
PPZ1FL and PPZ1cat are active, as they effectively dephosphorylate
a small molecule substrate mimetic (p-nitrophenyl phosphate
[pNPP]) (see Fig. S2 in the supplemental material). Furthermore,
their activities are identical to that of human PP1 purified from
E. coli (8) or PP1c (amixture of PP1 isoforms,, and ) purified
from rabbit muscle (17). However, unlike PP1, which expresses
solubly and crystallizes readily without its C-terminal disordered
residues (residues 301 to 330) (8), a PPZ1 construct truncated at
the corresponding residue (PPZ1cat466–484) is largely insoluble
compared to PPZ1cat (10-fold reduction in yield). This suggests
that the PPZ1cat C-terminal region is critical for folding and/or
stability. Consistent with this conclusion, the secondary structure
prediction programPSIPRED (18) predicts that these residues are
not disordered as they are in PP1 but instead form an -helix
(see Fig. S3 in the supplemental material).
The C-terminal residues of PPZ1cat are structured and form
an-helix. In order to understand themolecular consequences of
the sequence differences between PPZ1 and PP1 and the role of
the PPZ1 C-terminal residues in PPZ1 function, we determined
the 3-dimensional crystal structure of PPZ1cat to 2.61 Å resolution
(Table 1). ThePPZ1cat structure includes residues 171 to 478. (The
electron density for the last 6 residues, 479 to 484, was not ob-
served, and thus they were notmodeled.) As expected, the PPZ1cat
structure adopts the canonical PP1 fold (Fig. 2A and B), compris-
ing a mixed / protein, whose central loops are positioned to
coordinate the active site metals. However, the structures are not
identical. The rootmean square deviation (RMSD) between PP1
(PDB no. 4MOV [19]) and PPZ1cat is 1.23 Å (backbone). The
FIG 1 CaPPZ1 is a PP1-like phosphatase. Domain architecture of the PP1-
like phosphatases in C. albicans (GLC7-like, PPZ1, and PPQ1/Sal6 [pink]),
S. cerevisiae (green), andHomo sapiens PP1 (blue). Fungus-specific PP1-like
phosphatases have an N-terminal intrinsically disordered protein domain
(IDP [gray]) in addition to a structured C-terminal catalytic domain (pink/
green).
Chen et al.
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most significant difference is in the N-terminal region, where the
PPZ1cat helix A= extends for one more turn compared with PP1
and the loop connecting helix A= to helix A (L1) adopts a confor-
mation distinct from that in PP1 (Fig. 2B to D). (The RMSD of
L1 between PPZ1cat and PP1 is 2.99 Å.) Although the sequences
of L1 between PPZ1cat and PP1 are only 33% identical, this
change of conformation is primarily due to a single amino acid
change in helix C, Tyr144PP1 to Cys309PPZ1. The much smaller
cysteine side chain creates a hydrophobic pocket into which the
side chain ofVal193PPZ1 binds (Fig. 2D). Because this pocket is not
present in PP1, the corresponding PP1 residue, Val28PP1, in-
teracts directly with helix A=. As a consequence, the C atoms of
the two side chains are separated by 5.6 Å between the two struc-
tures. The rest of the PPZ1cat L1 conformation changes to accom-
modate this new interaction, which in turn widens the pocket
defined by helix A=, L1, and helix B (referred to here as the “Z1-
helix binding pocket”).
The newly widened Z1-helix binding pocket results in the sec-
ond significant structural difference between PPZ1cat and PP1:
the C-terminal residues of PPZ1cat are not disordered like they are
in PP1, but instead form an -helix that nestles into this newly
widened Z1-helix binding pocket (Fig. 2B to E). This interaction is
stabilized by hydrophobic interactions between the C-terminal
helix and residues from helices A= and B, with the interaction
centered on PPZ1 C-terminal helix residue Met473PPZ1 (Fig. 2E).
This residue is completely buried from solvent via interac-
tions with Leu464PPZ1, Leu469PPZ1, and Val472PPZ1 from the
C-terminal helix as well as by interactions with Phe185PPZ1 from
helix A= andHis235PPZ1, Ile238PPZ1, and Arg239PPZ1 from helix B.
The majority of these residues are not conserved in PP1. In par-
ticular, only a single residue (underlined) between the PPZ1
C-terminal helix and the C-terminal disordered tail of PP1 is
conserved (PPZ1, 466SAALKQVMKKEKQ478; PP1, 301KNKG-
KYGQFSGLN313), with the sequence of PPZ1 consisting of mul-
tiple hydrophobic residues and no helix-disrupting glycines
(Leu469PPZ1, Val472PPZ1, and Met473PPZ1 versus Gly304PP1,
Gly307PP1, and Gly311PP1, respectively), rationalizing why the
corresponding residues in PP1 are unstructured. Finally, the ex-
perimental B-factors for residues in the Z1-helix are higher than
the rest of PPZ1cat (Fig. 2F), suggesting that the Z1-helix is more
dynamic than the rest of the PPZ1cat.
The Z1-helix is dynamic.We also determined the structure of
PPZ1cat bound to the marine toxin microcystin-LR (MC
[PPZ1cat-MC]) (Table 1), a potent cyclic peptide inhibitor of PP1
(20). Both the MC-free and MC-bound structures of PPZ1cat are
highly similar, with an RMSD of 0.54 Å (Fig. 3A). The largest
difference is in the 12-13 loop, which contains Cys438PPZ1
(Fig. 3B). This cysteine forms a covalent bondwith the boundMC
identical to that observed in the PP1-MC complex (21). This
causes the 438CGEFD442 loop to change conformation and be-
comemore dynamic (residues 439GEF441 were not modeled in the
PPZ1cat-MC structure due to a lack of density). Unexpectedly, the
Z1-helix is also no longer ordered in the PPZ1cat-MC structure
(Fig. 3A). This was not due to MC binding, but instead the Z1-
helix was displaced by a symmetry-related molecule in the crystal.
The observation that the Z1-helix can be displaced supports the
observation that the Z1-helix is more dynamic than the rest of the
PPZ1cat. Importantly, the positions of L1 are identical between
the PPZ1cat and PPZ1cat-MC structures, demonstrating that the
conformation of L1 is intrinsic to PPZ1cat itself and not a conse-
quence of Z1-helix binding.
MC binds the active site of PPZ1cat essentially identically to
that observed in PP1 (Fig. 3C). Furthermore, the active sites are
also identical (Fig. 3D). The bulk of the MC binds the PPZ1cat
hydrophobic binding pocket (Fig. 3A), while the remainder covers
and, as a consequence, blocks the active site. The largest difference
between the conformations of MC in PP1-MC and PPZ1cat-MC
is a change of the rotomer conformation of the 1Zn residue phenyl
group and the Arg guanidinium group (Fig. 3C). The orientation
observed in PPZ1cat-MC is favored because a malonate ion from
the crystallizationmother liquor is bound in the rotomer position
populated in the PP1 structure; thus both positions are expected
to be equally likely in the absence of malonate. Furthermore, be-
cause the residues that mediate MC binding are highly conserved
between PPZ1cat and PP1 (79% identical and 90% similar [see
Fig. S1 in the supplemental material]), MC is predicted to inhibit
their activities with similar 50% inhibitory concentration (IC50)
values. We tested this in vitro using both small molecule (pNPP)-
andpeptide (myosin light chain [pMLC])-based substrates, which
show that the IC50 values of MC for all constructs are essentially
identical (IC50s for pMLC of 0.96 nM for PPZ1FL, 0.72 nM for
PPZ1cat, and 0.43 nM for PP1c, and IC50s for pNPP of 11.8 nM for
TABLE 1 Data collection and refinement statistics
Parameter
Value(s) fora:
CaPPZ1 CaPPZ1–microcystin-LR
Data collection
Space group C2221 P3221
Cell dimensions
a, b, c (Å) 145.0, 183.7, 69.0 50.7, 50.7, 201.1
, ,  (°) 90, 90, 90 90, 90, 120
Resolution (Å) 50.0–2.61 (2.66–2.61) 50.0–2.40 (2.44–2.40)
Rmerge (%) 13.3 (84.5) 6.6 (19.7)
I/I 14.1 (2.1) 30.6 (4.6)
Completeness (%) 99.9 (100.0) 98.5 (84.2)
Redundancy 5.6 (5.6) 6.1 (2.7)
Refinement
Resolution (Å) 36.24–2.61 43.9–2.40
No. of reflections 28,311 12,283
Rwork/Rfree 19.4/22.2 17.9/23.5
No. of atoms
Protein 4,922 2,314
Ligand/ion 32 23
Microcystin-LR NAb 71
Water 220 50
B-factors
Protein 33.0 30.8
Ligand/ion 29.9 46.6
Microcystin NA 35.5
Water 30.9 30.1
RMSDs
Bond lengths (Å) 0.002 0.003
Bond angles (°) 0.72 0.57
Ramachandran plot (%)
Favored regions 96.1 96.5
Allowed regions 3.8 3.5
Disallowed regions 0.2 0.0
PDB accession no. 5JPE 5JPF
a Values in parentheses are for the highest-resolution shell.
b NA, not applicable.
Structure of the Fungus-Speciﬁc CaPPZ1 Phosphatase
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PPZ1cat and 4.4 nM for PP1) (Fig. 3E; see Fig. S2 in the supple-
mental material).
The sequence and structural conservation of regulatory pro-
tein binding pockets in PPZ1cat is highly variable. While PP1
exhibits broad specificity, it acts in a highly specific manner by
forming stable complexes (holoenzymes)with a host of regulatory
proteins that direct PP1 activity toward specific substrates and
localize PP1 to specific regions of the cell (8, 22). Recent structural
studies have revealed that PP1 binds these regulators using small
linear interaction motifs (SLiMs) (7, 19, 23, 24). The most well-
FIG 2 The PPZ1-specific C-terminal helix. (A) Sequence alignment of CaPPZ1 (pink) and Homo sapiens PP1 (HsPP1 [blue]) with the observed secondary
structural elements indicated above the sequence. Identical residues are indicated by a star, similar residues are indicated by a colon, less similar residues are
indicated by a period, and dissimilar residues are indicated by a blank space. Resides from loop 1 (L1) and the PPZ1-specific helix are highlighted in yellow.
Arrows (yellow) indicate the hydrophobic residues in the PPZ1-specific helix that are not present in PP1. (B) The structure of PPZ1 is shownwith the secondary
structural elements discussed in the text labeled. (C) Overlay of PPZ1 (pink and yellow, as in panel B) and PP1 (blue). The change in conformation of loop L1
between the two structures is indicated by a dashed circle. (D) Stereo image of the overlay between L1 fromPPZ1 andPP1, colored as in panel C. (E) Interactions
between the PPZ1-specific C-terminal helix (yellow) and the widened PPZ1-specific helix binding pocket (coral). Residues that make key interactions are shown
as sticks and labeled. (F) PPZ1 colored according to residue B-factors, with yellow and green shading indicating higher B-factors.
Chen et al.
4 ® mbio.asm.org July/August 2016 Volume 7 Issue 4 e00872-16
 
m
bio.asm
.org
 o
n
 Septem
ber 2, 2016 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
known is the RVxF SLiM, which is found in ~70% of all known
regulators (22). Others include theMyPhoNE, SILK,, andArg
SLiMs (6, 7, 19, 23, 25). Mapping of the sequence differences onto
the structure of PPZ1cat shows that the bulk of the changes are
distally located from the active site (Fig. 4A). This comparison also
reveals that the RVxF interaction residues are 91% conserved be-
tween PPZ1 and PP1 (the only difference being a conservative
Met290PP1-to-Leu455PPZ1 substitution [Fig. 4B; see Fig. S1 in the
supplemental material]), suggesting that all PP1 regulators that
contain an RVxF sequence should bind PPZ1. Other sites are sim-
ilarly conserved. For example, inhibitor-2 (I-2) is a specific pro-
tein inhibitor of PP1. In addition to an RVxF and SILK motif, it
binds PP1 using a long helix, which binds across the PP1 active
site (25). Like the RVxF motif, the I-2 helix binding pocket is
highly conserved in PPZ1 (86% identical, 93% conserved
Fig. 4B; see Fig. S1) suggesting that I-2 can bind productively to
PPZ1. Likewise, the conservation of the NIPP1-helix interac-
tion pocket (70% identical and 80% conserved [Fig. 4B; see
Fig. S1]), also suggesting that this PP1 regulatory protein can
bind productively to PPZ1cat.
In contrast, other SLiM binding pockets are much less con-
served in PPZ1. For example, the SILK binding sites are only 71%
identical and 79% similar between PPZ1 and PP1 (Fig. 4B; see
Fig. S1 in the supplemental material). Three of the 4 amino acid
differences result in a change from an acidic to uncharged residue
(Glu56PP1/Ala221PPZ1, Asp166PP1/Ala331PPZ1, and Glu167PP1/
Gly332PPZ1). As these acidic residues coordinate the basic “K” of
the SILK motif, the “K” may not be necessary for PPZ1 to bind
SILK motif-containing proteins. The same is true for the My-
PhoNE binding pocket (23) (Fig. 4B; see Fig. S1). While the ma-
jority of residues that define the pocket are largely similar—57%
identical and 75% similar—multiple residues differ between the
two proteins (Asp179PP1/Val344PPZ1, Gln198PP1/Phe363PPZ1,
Gly215PP1/Glu380PPZ1, and His237PP1/Ser402PPZ1). The
Gly215PP1/Glu380PPZ1 substitution results in the largest clash in
the superimposed structures, with the Glu380PPZ1 side chain
clashing with that of Trp17MYPT1, suggesting that these changes
impact MYPT1 binding.
The SLiM binding pocket that is most different between PP1
and PPZ1 is the interaction site, with an identity of 22% and a
similarity of 67% (7, 19) (Fig. 4B; see Fig. S1 in the supplemental
material). The most significant differences are the replacement of
Tyr78PP1, which defines the  interaction pocket, with
Lys243PPZ1 and the replacement of Ala279PP1 with Trp444PPZ1.
Both Lys243PPZ1 and Trp444PPZ1 are large, bulky residues that
hinder access to the pocket. This suggests that PP1 regulators that
contain amotif will bind PPZ1 with lower affinity than PP1.
Finally, although the Arg interaction pocket is perfectly conserved
between both PP1 and PPZ1 (see Fig. S1), the presence of the
Z1-helix in PPZ1 is expected to negatively impact the binding of
FIG 3 The PPZ1-specific helix is dynamic. (A) Overlay of free PPZ1 (dark pink) and MC-bound PPZ1 (light pink). The C-terminal residues of both proteins
are labeled. The gray surface corresponds to the PPZ1-MC complex, illustrating that the PPZ1-specific helix was not ordered and thus not modeled (see the text
for details). The PPZ1 hydrophobic pocket is indicated by a dashed circle. (B) Enlarged view of the covalent bond between Cys438 andMC, resulting in a change
in conformation of the 12-13 loop. (Residues 439 to 441 were not visible in the PPZ1-MC structure and are indicated by a pink dashed line.) (C) Overlay of
MC from PPZ1 (light pink) and PP1 (blue). The Leu and Arg residues in microcystin-LR are labeled, as is the 1Zn [(2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-
2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid]. (D) Stereo image of the PPZ1 and PP1metal-bound active sites. BoundMn2 ions are shown as spheres.
(E) Dose-response curves reporting the inhibition of PP1c, PPZ1FL, and PPZ1cat activities by the MC toxin; 32P-labeled MLC20 was used as a substrate.
The phosphatase activities of each enzyme without toxin were set to 100% activity. The data represent the means  standard errors (SE) from 3
experiments.
Structure of the Fungus-Speciﬁc CaPPZ1 Phosphatase
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regulators that use this site for binding, especially those that also
use the  binding pocket. Because the Z1-helix binds between
these two sites, its presence will block access to the Arg site
(Fig. 4C), reducing the ability of PPZ1 to bind regulators that
contain these sequential SLiMs.
PPZ1 binds only a subset of PP1 regulatory proteins. To test
if PPZ1 binds differentially to known PP1 regulators, we used
pulldown assays with three well-characterized regulators—
GADD34, PNUTS, and spinophilin (Fig. 5A and B). The minimal
PP1-binding domains of these regulators bind PP1 with strong
affinities (Equilibrium dissociation constant [KD] values are
62 nM for GADD34552–567 [26], 9.3 nM for PNUTS394–433 [19],
and 8.7 nM for spinophilin417–602 [27]). As predicted, the pull-
down assays show that PPZ1cat binds GADD34 less effectively
than PP1 (Fig. 5C and D). Because the RVxF site is nearly per-
fectly conserved between PP1 and PPZ1cat, this suggests that the
weakened affinity is largely due to an inability of GADD34552–567
to productively bind the  motif binding pocket. To quantify
the reduction in binding, we used isothermal titration calorimetry
(ITC). The affinity of GADD34 for PPZ1cat decreases more than
19-fold, resulting in a KD of only 1,150  90 nM (Fig. 5E). Con-
sistent with this, peptides that contain only RVxFmotifs bind PP1
with KDs in the micromolar range (28), similar to those observed
for GADD34552–567 and PPZ1cat.
While the PP1 binding domain of GADD34 contains only an
RVxF motif andmotif, other regulators, such as PNUTS394–433
and spinophilin417–602 contain additional motifs that facilitate
PP1 binding (PNUTS, RVxF--Arg; spinophilin, RVxF–
–Arg–spinophilin417–602–helix [Fig. 5A and B]). We used
pulldown assays to determine if the altered binding pocket
and the presence of the Z1-helix negatively impact the binding
of these regulators to PPZ1 (Fig. 5C). The results show that
PPZ1, compared to PP1, does not effectively pull down either
PNUTS or spinophilin (~85% less binding [Fig. 5C and D]).
Furthermore, mutation of either the  or Arg motif in spi-
nophilin results in a similar reduction in PP1 binding, to levels
similar to those observed for PPZ1 and wild-type spinophilin
(see Fig. S4 in the supplemental material). Together, these data
demonstrate that the altered -binding pocket coupled with
the presence of the Z1-helix (Fig. 5B) negatively impacts the
FIG 4 PP1 regulatory protein binding pockets are differentially conserved in PPZ1. (A) Sequence conservation between PPZ1 and PP1 mapped onto the
surface of PPZ1. The yellow star indicates the location of the PP1 active site. (B) Close-up views of the RVxF,, SILK, I-2 helix, MyPhoNE helix, and NIPP1
helix binding pockets on PPZ1, with regulators that bind these pockets shown as sticks (RVxF,, and SILK) or a cartoon (I-2 helix,MyPhoNEhelix, andNIPP1
helix). The sequence changes between PP1/PPZ1 are indicated as in panel A. The sequence identity of the binding pockets is reported (see Fig. S1 in the
supplementalmaterial). (C)Overlay of a PP1 regulator (PNUTS [shownhere in orange]) that bridges the andArgmotif binding pockets onto PPZ1cat (rose).
The clash between the regulator and Z1-specific helix is shown.
Chen et al.
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ability of PPZ1 to interact with regulators that require these
sites for binding.
Thepresenceof theN-terminal IDPdomain reduces the abil-
ity of I-2 to inhibit PPZ1. Unlike GADD34, PNUTS, and spi-
nophilin, I-2 does not bind PP1 at the- or PPZ1-specific bind-
ing pockets. Instead, it binds PP1 using the SILK–RVxF–I-2–helix
interaction pockets (25). With the exception of the SILK motif
binding pocket, these interaction sites in PPZ1 are largely con-
served with those in PP1. Furthermore, the change in the SILK
binding pocket suggests that PPZ1 no longer has a strict require-
ment for the “K” residue (Fig. 4B). This suggests that I-2 will
inhibit both PPZ1 and PP1with equal potencies. To test this, we
measured the ability of I-2 to bind and inhibit PPZ1 activity and
compared it to that determined for PP1c. The data show that both
PPZ1cat and PP1c are inhibited by I-2with nearly equivalent IC50s,
measured to be 7 and 12 nM, respectively (Fig. 5F). However,
unexpectedly, we also discovered that I-2 is a much less potent
inhibitor against PPZ1FL, which includes the ~160-amino-acid
N-terminal IDP domain (see Fig. S3 in the supplemental mate-
rial).With PPZ1FL, the IC50 of I-2 increases 39-fold to 278 nM; this
increase was observed for both recombinant I-2 and I-2 partially
purified from rabbit muscle (not shown). (The latter result is con-
sistent with previous studies [29] that showed that S. cerevisiae
PPZ1FL is also poorly inhibited by I-2.) Furthermore, the specific
activities of the two PPZ1 constructs also differ significantly, with
4.6 mU/mg for PPZ1FL and 1,200 mU/mg for PPZ1cat. These data
FIG 5 Most PP1 regulatory proteins bind to PPZ1 less effectively. (A) Domain structure of the regulators tested (G34, GADD34552–567; PNUTS, PNUTS394–433;
Spino, spinophilin417–602) with their canonical PP1 interactionmotifs highlighted in different colors. (B) Structures of the GADD34 (blue; PDB no. 4XPN [26]),
PNUTS (orange; PDB no. 4MOY [19]), and spinophilin (gray; PDB no. 3EGG [27]) PP1 holoenzymes, with close-ups of the Z1 helix interaction pocket. (C) The
relative binding of PP1 and PPZ1with the regulators described in panel A was determined using a pulldown assay. (D) Densitometry analysis of the gel in panel
B. (E) Binding isotherm of GADD34552–567 with PPZ1cat (KD, 1,150 90 nM). (F) Dose-response curves of phosphatase activity with increasing concentrations
of I-2 with PP1c, PPZ1cat, and PPZ1FL phosphatases. The data represent the means SE from 3 experiments.
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suggest that the N-terminal domain likely masks one or more
binding sites for I-2 (but not the active site, as the PPZ1FL protein
is fully susceptible toMC inhibition [Fig. 3E]) and prevents, via an
as yet undetermined mechanism, PPZ1 inhibition by this protein
inhibitor.
DISCUSSION
Our structural and biochemical studies reveal why, in spite of their
high sequence similarity, fungus-specific phosphatases like PPZ1
bind only a subset of the GLC7-specific regulators (Fig. 6A). Spe-
cifically, we discovered that there are three distinctmechanisms by
which PPZ1 inhibits the binding of many GLC7-specific regula-
tors. First, sequence differences between PPZ1cat and PP1 in ca-
nonical SLIM interaction pockets, especially the  binding
pocket, inhibit the subset of regulators that requires these sites for
binding (see Fig. S1 in the supplemental material). Second, the
presence of the N-terminal IDP domain, which is not found in
GLC7, also negatively impacts the binding of at least some regu-
lators (e.g., I-2), likely through an as yet undefined steric mecha-
nism (Fig. 5 and 6A). Third, structural differences between
PPZ1cat and PP1 can also negatively impact regulator binding. In
particular, our data show that the presence of the Z1-specific helix
hinders access to theC-terminal groove by regulators that bind the
Arg site via the site (Fig. 5). In addition, the dynamic nature of
this helix raises the intriguing possibility that it may also serve a
regulatory role in PPZ1 function. Finally, the binding pocket of
the Z1-specific helix is also unique, as that of PP5, the only other
known serine/threonine protein phosphatase with a C-terminal
helix, binds at the front, versus the top, of the core catalytic do-
main (Fig. 6B) (30). Together, these results show that instead of
PPZ1 competing with GLC7 for its regulators, the regulators pref-
erentially bind and control the activity of GLC7 (Fig. 6A). This
resolves a long-standing question about why the presence of the
fungus-specific phosphatases does not globally disrupt GLC7
function (12).
Our studies also revealed that multiple pockets in PPZ1cat are
unique to this phosphatase and thus can be exploited for drug
development. While the PPZ1cat and PP1 active sites are per-
fectly conserved, the conformation of loop L1 is unique in
PPZ1cat, as is its folded Z1-specific helix. Both of these new struc-
tural elements create novel binding surfaces that are not present in
human isoforms of PP1. Thus, they are useful for the development
of specific, potent antifungals. Because their active sites are per-
fectly conserved, one strategy for developing a fungus-specific in-
hibitor of PPZ1 would be to use “fragment linking” (31): i.e.,
linking a small molecule that targets one of the unique PPZ1-
specific binding pockets with a small molecule that, for example,
targets the PP1 active site. This would result in an inhibitor that
selectively targets PPZ1, as it would bind PPZ1 with higher
affinity than human PP1 isoforms. Because PPZ1 is critical for
C. albicans hypha formation, a morphological change associ-
ated with infectivity, this type of PPZ1-specific inhibitor would
stop C. albicans infections without killing the commensal
pathogen. This would prevent uncontrolled bacterial prolifer-
ation that can accompany C. albicans elimination and thus will
result in novel, potent drugs with minimal side effects for the
treatment of candidemia.
MATERIALS AND METHODS
Protein expression, purification for pNPP-based assays, and crystallog-
raphy. The gene encoding PPZ1cat (aa 171 to 484) was synthesized (Ge-
neArt; Invitrogen), subcloned into the RP1B bacterial expression plasmid
(32), and expressed largely as previously described (8). Specifically, the
plasmid was cotransformed with the pGRO7 plasmid, which encodes the
GroEL/GroES chaperone (TaKaRa), into E. coli BL21(DE3) cells (Invitro-
gen). Cells were grown in LBmedium supplemented with 1mMMnCl2 at
30°C to an optical density at 600 nm (OD600) of ~0.5, at which point
arabinose was added (2 g/liter) to induce the expression of the GroEL/
GroES chaperone. At an OD600 of ~1, the temperature was lowered to
10°C, and the expression of PPZ1 was induced using 0.1 mM IPTG (iso-
propyl--D-thiogalactopyranoside): the protein was allowed to express
for ~20h at 10°C. The cells were harvested by centrifugation, suspended in
fresh LBmedium (again supplemented with 1mMMnCl2 and 200g/ml
of chloramphenicol to inhibit the ribosome), and agitated for ~5 h at
10°C. Harvested cells were frozen and stored at	80°C.
All purifications were performed at 4°C. Cells expressing His6-tagged
tobacco etch virus (TEV) protease sequence-PPZ1cat were lysed in lysis
buffer (25 mM Tris [pH 8.0], 700 mM NaCl, 5 mM imidazole, 1 mM
MnCl2, 0.1% Triton X-100) using high-pressure homogenization (Aves-
tin C3 EmulsiFlex) in the presence of an EDTA-free protease inhibitor
cocktail (Roche). The lysate was clarified by centrifugation at 45,500
 g,
filtered through a 0.22-m-pore polyethersulfone (PES) membrane filter
(Millipore), and then loaded onto Ni2-nitrilotriacetic acid (NTA) resin
(GE Healthcare) preequilibrated in buffer A (25 mM Tris [pH 8.0],
700 mM NaCl, 5 mM imidazole, 1 mM MnCl2). Bound His6-TEV-
PPZ1cat was washed with 100 ml of buffer A, followed by more stringent
wash with 100 ml “stringent wash buffer” consisting of 94% buffer A and
6% buffer B (25 mM Tris [pH 8.0], 700 mM NaCl, 250 mM imidazole,
FIG 6 Features of PPZ1 that limit its interaction with GLC7 regulators. (A) Cartoon illustrating that the presence of the disordered N-terminal domain,
the lack of conservation of key PP1/GLC7 interaction domains (such as the  binding pocket), and the presence of the PPZ1-specific helix negatively
impact the binding of PPZ1 with many GLC7-specific regulators, leaving the regulators to preferentially bind and regulate the activity of GLC7. (B)
Overlay of PPZ1 (pink) and PP5 (blue; PDB no. 1S95 [30]), illustrating that the C-terminal helices of the two proteins bind different pockets in the core
PSP catalytic domain.
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1 mM MnCl2). The bound His6-TEV-PPZ1cat was eluted using 100%
buffer B and immediately purified by size exclusion chromatography
(SEC) using Superdex 75 26/60 preequilibrated in 20 mM Tris (pH 8.0),
500 mM NaCl, 0.5 mM Tris(2-carboxyethyl)phosphine (TCEP), and
1 mM MnCl2. Fractions containing the His6-TEV-PPZ1cat protein were
pooled and incubated overnight with TEV protease at 4°C. A second
Ni2-NTA “subtraction” purification was used to separate cleaved
PPZ1cat from the cleaved His6 tag and TEV; the flowthrough, which con-
tained the cleaved PPZ1cat, was pooled and purified in a final step using
SEC. PPZ1cat was pooled, concentrated, and used immediately for crys-
tallization experiments.
Protein expression and/or purification for dephosphorylation as-
says.The catalytic subunit of rabbit skeletal muscle protein phosphatase 1
(PP1c) was isolated as described (33). The 20-kDa myosin light chain
(MLC20) and the myosin light chain kinase (MLCK) were obtained from
turkey gizzard, andMLC20was phosphorylated byMLCK in the presence
of [-32P]ATP and Mg2 as described previously (34). Recombinant
6
His-tagged inhibitor-2 (I-2) was prepared as described previously
(28); I-2 was also isolated from rabbit skeletal muscle (35) for some con-
trol experiments.
The coding sequences for full-length Candida PPZ1FL and its con-
served C-terminal catalytic domain, termed PPZ1cat, were generated
by PCR from the pET28-CaPPZ1 plasmid (GenBank accession no.
GQ357913 [14, 36]) and cloned into the E. coli expression vector
pGEX6p-1 (Amersham Biosciences); both constructs were sequence ver-
ified (UD Genomed, Ltd.). Both constructs were then transformed into
E. coli BL21(DE3) RIL cells (Agilent), and expression of N-terminal glu-
tathione S-transferase (GST)-tagged proteins was induced with 0.6 mM
IPTG (Sigma) at 18°C. Overnight incubation was used to express GST-
PPZ1cat, while a shorter, 3-h incubation period was required to reduce
inclusion body formation and ensure optimal production of soluble
GST-PPZ1FL. In both cases, 0.5 mMMnCl2 was included in the culture
medium, and 1 mM MnCl2 was present during the subsequent purifi-
cation steps. The fusion proteins were purified using glutathione-
Sepharose 4B (GE Healthcare) resin, and the GST tag was removed
using the PreScission protease (GE Healthcare) during elution (fol-
lowing the instructions of the manufacturer). The protein concentra-
tion was determined using the Bradford assay, and protein purity was
verified by SDS-PAGE.
Protein phosphatase assays. The activities of the recombinant C. al-
bicans phosphatases were measured with 32P-labeled MLC20 substrate as
previously described (34), with the exception that the substrate concen-
tration was 1 M and 2 mM MnCl2 was included in the assay mixtures.
The activity of rabbit PP1 was also determined under identical condi-
tions as a control. The 50% inhibitory concentrations (IC50s) of
microcystin-LR (obtained from Enzo Life Sciences or purified as previ-
ously described [37]) were determined by using either the protein sub-
strate or a small molecule substrate as described previously (38), except
that pNPP (Sigma-Aldrich) was used instead of 3-O-methylfluorescein
phosphate (OMFP). Reactions were carried out in 96-well plates (Costar).
MC concentrations were prepared by serial dilution and added to 150 l
of buffered enzyme (18 nM protein in 40 mMHEPES [pH 7.0], 1.33 mM
dithiothreitol [DTT], 1.33% [vol/vol] Triton X-100, 0.133 mg/ml bovine
serum albumin [BSA], 1.33 mM sodium ascorbate, 1.33 mM MnCl2) in
wells containing the reactionmixtures. The high-signal controls were pre-
pared by adding dimethyl sulfoxide (DMSO), matching the amount pres-
ent in the reaction mixture with the highest concentration of MC. The
low-signal controls were the reaction mixtures containing the highest
concentration of microcystin-LR. The reactions were initiated by the ad-
dition of pNPP substrate and incubated at room temperature for 30 min.
The reactions were stopped using 100l of 300mMpotassiumphosphate
(pH 10). The absorbance was measured at 405 nm using an Epoch spec-
trophotometer (BioTek). The percentage of activity of each protein was
calculated using the equation [(absorbance	 low-signal control)/(high-
signal control 	 low signal control)] 
 100%. The IC50 was then calcu-
lated using SigmaPlot 12.5.
Crystallization and structure determination. Crystals of apo-
PPZ1cat were obtained using hanging drop vapor diffusion in 1.8 M am-
monium citrate tribasic (pH 7.0) in a 2:1 protein/crystallization condition
ratio. To generate PPZ1cat-MC crystals, PPZ1cat was first incubated with
MC at a 1:1 molar ratio for 15 min before crystallization using hanging
drop vapor diffusion in 0.06 M citric acid (pH 4.1) plus 16% (wt/vol)
polyethylene glycol (PEG) 3350. For data collection, crystals were first
cryo-protected with 30% glycerol in mother liquor (PPZ1cat) or 3.4 M
Na-malonate (pH 4.0) (PPZ1cat-MC) and then flash-frozen in liquid ni-
trogen. X-ray data were collected in house at 100 K using a Rigaku FR-E
Superbright rotating copper anode X-ray generator with a Saturn 944
HG charge-coupled device (CCD) detector (Brown University Structural
Biology Facility). The data were phased using molecular replacement
(Phaser as implemented in PHENIX [39]) using PP1 (PDB no. 4MOV
[19]) as the searchmodel. Clear electron density ofMC could be observed
bound to the active site. The initial models were built using Phenix.Auto-
Build (40) followed by iterative rounds of refinement in PHENIX and
manual building using Coot (41).
Isothermal titration calorimetry. GADD34552–567 peptide was pur-
chased from Biosynthesis, Lewisville, TX. The peptide was dissolved di-
rectly in ITC buffer (20 mMTris [pH 8.0], 500 mMNaCl, 0.5 mMTCEP,
1 mMMnCl2). GADD34552–567 was titrated into PPZ1cat using a VP-ITC
microcalorimeter at 25°C (Microcal, Inc.). Data from the ITC runs were
analyzed using Origin 7.0.
Pulldown assay. GADD34552–567 was purchased. PNUTS394–433 and
spinophilin417–602 were purified according to a method described previ-
ously (19, 27). Spinophilin417–602¡AA, R469D, and R469E mutants
were generated using site-directed mutagenesis. PP17–330 and PPZ1cat
were purified by the method described above but retained the His tag.
After SEC (20 mM Tris [pH 8.0], 500 mM NaCl, 0.5 mM TCEP, 1 mM
MnCl2), 50% (vol/vol) glycerol was added to both PP17–330 and PPZ1cat.
The final concentrations of the proteins were adjusted to 5 M. Ten mi-
cromoles of each PP1 regulator was added into 500 l of PP17–330 or
PPZ1cat. The mixture was incubated under rocking (4°C) for 60 min to
allow for complex formation. A 15-l bed volume of Ni-NTA resin (GE
Healthcare) was added into tubes, and the mixture was incubated at 4°C
for 60 min. The beads were pelleted by centrifugation (2000 
 g) and
washed three times with 500 l of SEC buffer. Forty microliters of SDS
loading bufferwas added to the beads, and the sampleswere boiled at 80°C
for 5 min and analyzed on NuPAGE 4 to 12% bis-Tris gels. Gels were
stained overnight with SYPRO ruby protein gel stain (Life Technologies)
according to the manufacturer’s protocols and scanned using a Typhoon
9410 laser scanner (GE Healthcare) with an excitation wavelength of
457 nm and emission filter of 610 nm following destaining. Densitometry
was performed using ImageQuant TL 7.0 software for quantification of
the band intensity.
Accession number(s). Atomic coordinates and structure factors have
been deposited in the Protein Data Bank under accession no. 5JPE for
PPZ1 and 5JPF for PPZ1-MC.
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